| Stage | BG | % of rev | CENX | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $23.8B | 100.00% | $752M | 100.00% | BG ×31.65 |
| Gross profit | $1.3B | 5.60% | $228M | 30.30% | CENX +24.7pp |
| Operating income | $727M | 3.05% | $212M | 28.13% | CENX +25.1pp |
| Pre-tax income | $515M | 2.16% | $257M | 34.16% | CENX +32.0pp |
| Net income | $347M | 1.46% | $244M | 32.42% | CENX +31.0pp |
| Stage | BG | CENX | Gap · A − B |
|---|---|---|---|
| Revenue | $23.8B100.00% | $752M100.00% | BG ×31.65 |
| Gross profit | 5.60%$1.3B | 30.30%$228M | CENX +24.7pp |
| Operating income | 3.05%$727M | 28.13%$212M | CENX +25.1pp |
| Pre-tax income | 2.16%$515M | 34.16%$257M | CENX +32.0pp |
| Net income |
| 1.46%$347M |
| 32.42%$244M |
| CENX +31.0pp |
None
No disclosed counterparties: BG.